Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Bladder, Kidney and Genitals

A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder

In this plain language summary published in Journal of Comparative Effectiveness Research, learn about a study that looked at how likely it is that individual people with overactive bladder will achieve a certain level of improvement in their symptoms when taking fesoterodine.

Read the full article here.

The original article on which this summary is based is called ‘What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine’ and was originally published in the journal Neurourology and Urodynamics here.

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

This is a summary of a publication about the ARASENS trial, which was published in the New England Journal of Medicine in February 2022. The ARASENS trial looked at how well darolutamide worked when combined with androgen deprivation therapy (ADT) and docetaxel compared placebo plus ADT and docetaxel in men with metastatic, hormone-sensitive prostate cancer. The summary also includes perspectives on the ARASENS trial and prostate cancer from 3 members of the patient community.

Read the full article here.

Click here to read the original article on which this summary is based.

Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer

The HERO study compared how well relugolix and leuprolide worked in lowering blood testosterone to sustained castration levels in men with advanced prostate cancer. This is plain language summary provides an overview of this study.

Read the full article here.

Click here to read the original article on which this summary is based.

Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

The latest plain language summary of publication (PLSP) published in Future Oncology provides a summary of the ARAMIS trial, which looked at the role of darolutamide in the treatment of patients with nonmetastatic, castration-resistant prostate cancer. The article entitled ‘Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial’ is a summary of the original ARAMIS publication from the New England Journal of Medicine published September 2020.

As well as providing details on the trial itself, the summary also includes insights and perspectives from a participant who was in the ARAMIS trial and from a prostate cancer patient advocate.

After five years in the ARAMIS trial, I have been very pleased to see the positive outcomes of the trial which has given me hope for a continued good quality of life for the foreseeable future

I Blue

Read the PLSP, with accompanying animated video, here.

The original article ‘Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide’, published in the New England Journal of Medicine, can be found here.